5HT1a Receptor Binding Affinities of a Series of Serotonin Transporter (SERT) Inhibitors and Related Thermodynamic Insights^

Gisella E. Alfonsino¹, Andrea Santagati¹, Livia Basile¹, Ettore Novellino², Corey Gaul³, Carley Squires³, Michael Braden³, John M. Gerdes³, Silvia Pérez Silanes⁴, Salvatore Guccione¹* and Keith K. Parker³

¹Department of Drug Sciences, University of Catania, V.le A. Doria 6 Ed. 2 Città Universitaria, I-95125 Catania, Italy.
²Department of Pharmacy, University of Napoli “Federico II”, via D. Montesano 49, I-80131 Napoli, Italy.
³Department of Biomedical and Pharmaceutical Sciences (BMED), Skaggs School of Pharmacy and Pharmaceutical Sciences, Center for Structural and Functional Neurosciences, The University of Montana, Missoula, MT 59812-1552, USA.
⁴Department of Organic Chemistry, University of Navarra, Edificio de Ciencias C/Irunlarrea, 1- Es-31008 Pamplona (Navarra), Spain.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors JMG, SG and KKP designed the study and wrote the protocol. Authors JMG, CG, CS, MB and KKP collected all data and performed the statistical analysis. Authors SG, KKP and SPS wrote the first draft of the manuscript. Authors GEA, LB, SPS and AS did the literature search and also wrote part of the manuscript. Authors EN, JMG, SG and KKP wrote the final version of the manuscript. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMPS/2015/18917

Editor(s):
(1) Jinyong Peng, College of Pharmacy, Dalian Medical University, Dalian, China.

Reviewers:
(1) Peizhong Mao, Oregon National Primate Research Center, USA.
(2) Anonymous, Universidad Veracruzana, Mexico.
(3) Anonymous, Taiwan.
(4) Anonymous, University of Missouri, USA.

Complete Peer review History: http://sciencedomain.org/review-history/10238

Received 16th May 2015
Accepted 4th July 2015
Published 19th July 2015

Original Research Article

*Corresponding author: E-mail: guccione@unict.it;
ABSTRACT

Clinical depression encompasses a complex neurobiology involving multiple interacting systems. This intricate pathophysiology is, in part, correlated with dysfunction in serotonin (5HT) neurochemistry. The 5HT1a receptor (R) and SERT (serotonin transporter) components of this network are highly correlated to mood and anxiety regulation and difficulties in this regard in the realm of depression.

Aims: The current study was designed to develop a series of arylpiperazine derivatives ligands that are antagonists at both H5HT1aR and SERT.

Study Design: Development of new chemotype antagonists at H5HT1aR and SERT.

Place and Duration of Study: University of Catania (Italy) and University of Montana, Missoula, Montana, May 2008 to June 2013.

Methodology: Chinese Hamster Ovary cells transfected with the gene for the Human (H) 5HT1a Receptor were cultured, and membranes containing the receptor were prepared for competition assays between the test compounds and the agonist, [3H]8-OH-DPAT. For thermodynamics, K_i's were determined at a series of temperatures from 0-35 degrees C. Further, membranes from rat brain were utilized for competition assays between the test compounds and the SERT inhibitor, [3H]paroxetine.

Results: Many of these substances show nanomolar affinities at H5HT1aR, and a number of the compounds also have high efficacy in inhibiting SERT. It is of note that some members of this series also substantially discriminate between binding at H5HT1aR and H5HT7R, a receptor studied with these compounds in previous work. Thermodynamic properties for the compound 4-[4-(3-benzo[b]thiophen-3-yl-3-oxopropylamino) piperidin-1-yl] benzonitrile (BTPN; compound15) are also reported.

Conclusions: There are a few of these compounds that excel in all three categories of H5HT1aR affinity, SERT inhibitory activity, and discriminatory binding capacity between the two receptors. Implications in the context of clinical needs in depression and other nervous systems disorders are discussed.

Keywords: Clinical depression; serotonin; 5-HT1A receptor; SERT; thermodynamics studies.

1. INTRODUCTION

The neurobiology of depression [1,2] has been under intense study; multiple neuronal and hormonal systems are involved in the pathophysiology [3,4,5] and complexity [6,7] has been observed in genetic, epigenetic, and environmental events. Evidence suggests an immunologic connection as changes in the immune system influence corticosteroids, perhaps via cytokines IL1 and 6; other signaling pathways including the serotonergic (5HT) are altered. 5HT [8,9] plays a critical role overall [10]. Dys-regulation of 5HT may present vulnerability to a variety of mental disorders including mood regulation [11,12].

The inter-relationships between 5HT, stress [3,13] and increased secretion of cortisol have been noted. These events are due to the link between anxiety and depression [14,15,16].

Coupling of depression to anxiety is but one of many connections being identified between depression and heretofore separate phenomena [17,18,4,19,3]. For example, the metabolic regulator, leptin, has been implicated in regulation of mood. When stressors are extended by intensity and duration, anxiety and depression may ensue. 5HT drugs have a role in returning to homeostasis.

Serotonin (5-hydroxytryptamine; 5HT) receptors (5HTR) are major components of this analysis [20,21,22]. Many of the 5HTR are G Protein-Coupled Receptors (GPCR) [23]. The first crystal structures for 5HTR have opened a new era for 5HT pharmacology [24]. One of the 5HTR sub-types, the 5HT1aR [25] is involved in depressive disorders [26,27]. A meta-analysis has shown H5HT1aR dys-regulation to be correlated with major depressive disorder [28]. At the biochemical level there is evidence to support involvement of both somatodendritic receptors in the raphe nuclei and/or post-synaptic receptors in various brain regions. Evidence suggests that anti-depressant actions are fortified by antagonism at the raphe autoreceptors and agonism at the post-synaptic sites. In Deaf-1 mutant mice, raphe autoreceptors are up-regulated and hippocampal post-synaptic 5HT1a receptors are down-regulated. This produces
behavior consistent with increased anxiety and decreased responsiveness to 5HT transport (SERT) inhibitors (SSRI) [29], potentially of therapeutic importance [30].

Involvement of 5HT1aR not only influences 5HT transmissonal homeostasis [25] but other systems such as the corticostereoid [31] and glutaminergic [16]; in turn, chronic cortisol secretion desensitizes 5HT1aR. More evidence comes from post-mortem studies [27] and positron emission tomography (PET) studies in humans using high affinity antagonists show 5HT1aR involvement in anxiety and depression as well as the action of anti-depressant drugs, like transport inhibitors [32]. One specific instance is that involving the 5HT1aR and cannabinoinds (CBD: cannabidiol) [33,34] in treating an anxiety disorder, panic [35].

Our laboratories have addressed differential activities of a series of aryppyperazin derivatives at SERT and 5HT1aR [36,37,38,39]. Structurally, the benzo[b]thiophene group is related to SERT inhibition with the aryppyperazin group related to activity at 5HT1aR. These observations were expanded to differential binding to SERT [40,41] vs. 5HT7R [22,42], which is also an anti-depressant target [43], and which has been receiving attention as a neurobiological target [44]. Aryppyperazinylbutyloxindoles have 5HT1a /5HT7/alpha 1 adrenergic actions [45,46]. Our laboratories have focused on the 5HT1aR binding site [47,48,49] and at the receptor/G protein interface [50,51]. The present study focuses on differential benzo [b] thiophene-aryppyperazin activity at SERT versus H5HT1aR with reference to H5HT7R.

There is a small literature on the thermodynamics of binding site ligands at 5HT1aR [51,52,53,54]. Results from the present investigation are the first reported thermodynamics for a new series of ligands [43] interacting with the human 5HT1aR. These preliminary results should be useful, in combination with receptor-based biochemistry and pharmacology using different techniques, to develop better models of the H5HT1aR/G protein system, ultimately producing advances in applied drug development.

2. MATERIALS AND METHODS

2.1 Compound Synthesis and Preparation

The compounds involved in this paper were prepared as previously reported and their structures are presented in Table 1. and Table 2. [43,36,37,38,39].

2.2 Cell Culture

Chinese Hamster Ovary (CHO) cells expressing the human (H) 5HT1aR [55,56] were cultured in Ham's F-12 medium plus 10% fetal calf serum and 200 μg/ml geneticin. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂. Cells were sub-cultured (trypsin) or assayed upon confluency (5-8 days). Clone H5HT1aR was kindly provided by Dr. John Raymond, the Medical University of South Carolina [57].

2.3 Receptor Preparation

Cells were trypsinized and centrifuged; the pellet was re-suspended in Earle’s Balanced Salt Solution followed by centrifugation. Cells were resuspended in 10 ml of binding buffer (50 mMTris, 4 mM CaCl₂, 10 μM pargyline, pH 7.4), homogenized with Teflon-glass, and centrifuged for 450000 g-min. at 4°C (10000 g for 45 min. at 4°C). The pellet was re-suspended in 30 ml of ice-cold binding buffer, and homogenized, with Teflon-glass and then with a Polytron (setting 4) for 5 sec. The preparation was stored on ice and used within 1.5 hrs [51].

2.4 Assay of Receptor Activity

Binding of agonist [³H] 8-OH-DPAT ([³H] 8-hydroxy-2-(di-n-propylamino)tetralin) to H5HT1aR followed well-characterized protocols [50]. Radioligands were from New England Nuclear, Boston, MA. 1 ml reaction mixtures, in triplicate, were incubated for 30 min. in a 30°C shaker bath. Composition of the 1 ml reaction mixture: 700 μl of receptor preparation; 100 μl of either binding buffer (for total binding) or 10 μM 5-HT (final concentration for non-specific binding), 100 μl of the tritiated agent (0.5 nM) and 100 μl of test ligand or binding buffer for controls.

Reactions were stopped in 4 ml of ice-cold 50 mMTris buffer, pH 7.4, and vacuum filtration on glass fiber filters (Whatman GF/B). Filters were rinsed twice in 5 ml of ice-cold Tris buffer, dried, and counted in 5 ml of Ecoscint (National Diagnostics) in a Beckman LS 6500 instrument. Homogenates were assayed for protein to maintain a nominal value of 50 μg protein per filter [58]. For the thermodynamics, receptor binding assays were conducted as outlined earlier in this section. As described in greater
detail in an earlier publication [51] the following parameters were utilized: concentration of compound 15, 10 nM (its apparent Kd); [3H]β-OH-DPAT ranging from 0.2 to 2.0 nM (apparent Kd of about 0.6 nM); and Centigrade temperatures of: 0, 15, 25, 30 and 35 degrees.

Table 1. Ki’s for the ketone set of compounds at the HSHT1aR and binding at the rat SERT

| Code (#) | Comp. | Arylamine | Ki H5HT1aR | SERT (1/10 μM) % Activity remaining |
|---------|-------|-----------|------------|-----------------------------------|
| E0005 (3) | 1<sup>a</sup> | -N=N-Cl | 0.8 +/- 0.06 μM | 87 +/- 10/33/+/-1 |
| E0009 (4) | 2<sup>a</sup> | -N=N-Cl | 0.52 +/- 0.03 μM | 90 +/- 12/36/+/-3 |
| E11 III 27 (36) | 3<sup>a</sup> | est. > 2 μM | 98 +/- 17/67/+/-11 |
| E11 III 29(48) | 4<sup>a</sup> | -N=N-CN | 0.38 +/- 0.024 μM | 95 +/- 1/62/+/-5 |
| E11 III 214(11) | 5<sup>a</sup> | est. > 2 μM | ND |
| E11 III 01(39) | 6<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 1.9 +/- 0.13 μM | 94 +/- 1/77/+/-21 |
| E11 III 02(40) | 7<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 1.2 +/- 0.07 μM | 99 +/- 2/77/+/-8 |
| E11 III 03(9) | 8<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 1.04 +/- 0.05 μM | 100 +/- 10/45/+/-7 |
| E11 III 04(41) | 9<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 1.8 +/- 0.05 μM | ND |
| E11 IV 27 (12) | 10<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 0.42 +/- 0.013 μM | 77 +/- 11/32/+/-9 |
| E11 IV 212(14) | 11<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 0.45 +/- 0.02 μM | 99 +/- 6/37/+/-7 |
| E11 IV 214(15) | 12<sup>a</sup> | -N=N-SO<sub>2</sub>-Cl | 0.52 +/- 0.03 μM | 76 +/- 10/42/+/-12 |
| E11 VIII 27(22) | 13<sup>a</sup> | -N=N-CN | 31 +/- 2 nM | ND |
| E11 VIII 212 (24) | 14<sup>a</sup> | -N=N-CN | 10.4 +/- 0.7 nM | ND |
| E11 VIII 28 (23) | 15<sup>a</sup> | -N=N-CN | 7 +/- 1 nM | 73 +/- 5/37/+/-1 |
| E11 VI 28 (R) (21) | 16<sup>a</sup> | -N=N-CN | 7.8 +/- 0.5 nM | 84/69 |
| E11 VI 28 (S)(18) | 17<sup>a</sup> | -N=N-CN | 16 +/- 0.6 nM | 72 +/- 10/2/+/-14 |
| E11 VI 27(S) (17) | 18<sup>a</sup> | -N=N-CN | 0.73 +/- 0.04 μM | 106 +/- 6/63/+/-3 |
| E11 VI 212(S) (19) | 19<sup>a</sup> | -N=N-CN | 2.1 +/- 0.08 μM | 102 +/- 19/54/+/-14 |
| E11 VI 06(46) | 20<sup>a</sup> | -N=N-CN | 93 +/- 4 nM | ND |
| E11 VII 27(R) (20) | 21<sup>a</sup> | -N=N-CN | 0.64 +/- 0.04 μM | 91 +/- 14/55/+/-2 |
| E11 V 27(16) | 22<sup>a</sup> | -N=N-CN | 0.23 +/- 0.01 μM | 82 +/- 1/24/+/-5 |
| E11 V 28 (58) | 23<sup>a</sup> | -N=N-CN | 0.36 +/- 0.01 μM | 132 +/- 1/136/+/-4 |
| E11 IX 216 (25) | 24<sup>a</sup> | -N=N-CN | 3.0 +/- 0.2 μM | 89 +/- 10/70/+/-17 |
| E21 III 27 (34) | 25<sup>a</sup> | -N=N-CN | 0.28 +/- 0.01 μM | 106 +/- 14/84/+/-7 |
| E21 III 05 (33) | 26<sup>a</sup> | -N=N-CN | 1.1 +/- 0.08 μM | 107 +/- 3/45/+/-4 |
| E21 II 27 (38) | 27<sup>a</sup> | -N=N-CN | 49 +/- 3 nM | 106 +/- 14/84/+/-7 |

Results are mean +/- standard error of the mean. Drugs are from the following previously published investigations:
(a) Berrade et al., [43]; (d) Orus et al., [38]; and (e) Perez-Silanes et al., [39]. ND: Experiment Not Performed
Table 2. Ki’s for the hydroxy set of compounds at the H5HT1aR and activity at the rat SERT

| Code #   | Comp. | Ar | Arylamine | Ki H5HT1aR | SERT (1/10μM) %Activity remaining |
|---------|-------|----|-----------|------------|----------------------------------|
| E0014 (7) | 29°   |    |           | 0.31 +/- 0.02 μM | 109 +/- 1/61 +/- 4 |
| E0015 (8) | 30°   |    |           | 0.64 +/- 0.05 μM | 88 +/- 6/41 +/- 15 |
| E12 III 212 (51) | 31a   |    |           | 1.0 +/- 0.03 μM | 83 +/- 9/62 +/- 1 |
| E0012 (6) | 32°   |    |           | 2 +/- 0.2 nM | 109 +/- 7/53 +/- 3 |
| E0004 (2) | 33°   |    |           | 1.6 +/- 0.13 nM | 66 +/- 1/30 +/- 4 |
| E12 III 02 (26) | 34a   |    |           | est. > 2 μM | 85 +/- 11/52 +/- 2 |
| E12 III 03 (43) | 35a   |    |           | 1.4 +/- 0.1 μM | 105 +/- 12/73 +/- 10 |
| E12 III 04 (44) | 36a   |    |           | 0.85 +/- 0.08 μM | 109 +/- 1/71 +/- 1 |
| E12 IV 27 (27) | 37a   |    |           | 0.47 +/- 0.03 μM | 70 +/- 6/52 +/- 18 |
| E12 IV 212 (53) | 38a   |    |           | 1.2 +/- 0.06 μM | 80 +/- 9/63 +/- 14 |
| E12 IV 28 (28) | 39a   |    |           | 0.44 +/- 0.03 μM | 115 +/- 23/64 +/- 11 |
| E12 VIII 27 (31) | 40°   |    |           | 100 +/- 6 nM | 60/7 |
| E12 VIII 212 (54) | 41°   |    |           | 50 +/- 3.2 nM | 64/7 |
| E12 VIII 28 (57) | 42°   |    |           | 22 +/- 2 nM | 169 +/- 20/114 +/- 1 |
| E12 VI 27 (S) (29) | 43a   |    |           | 0.55 +/- 0.02 μM | 72 +/- 11/51 +/- 4 |
| E12 VI 28 (30) | 44°   |    |           | 76 +/- 3 nM | 78 +/- 7/62 +/- 21 |
| E12 IX 216 (32) | 45°   |    |           | est. > 2 μM | 98 +/- 9/36 +/- 11 |
| E22 III 27 (50) | 46°   |    |           | 1.2 +/- 0.09 μM | 81 +/- 12/74 +/- 12 |
| E0011 (5) | 47c   |    |           | 0.16 +/- 0.01 μM | 90 +/- 8/47 +/- 6 |
| E0002 (1) | 48°   |    |           | 0.64 +/- 0.05 nM | 80 +/- 8/43 +/- 4 |
| E22 III 04 (35) | 49a   |    |           | est. > 2 μM | 121 +/- 12/82 +/- 7 |

Results are mean +/- standard error of the mean. Compounds are from the following previously published investigations: (a) Berrade et al., [43]; (b) Martinez et al., [36]; (c) Martinez-Esparza et al., [37]; (d) Orus et al., [38]; and (e) Perez-Silanes et al [39].

2.5 SERT Assay

The in vitro inhibitory capability of ligands was determined using a rat cortical SERT competition assay [59] with [3H] paroxetine. The assays were performed with aliquots of partially purified rat cortex membrane (Pel-Freeze Biologicals, Inc.). Suspensions were incubated with 0.25 nM [3H] paroxetine (DuPont-NEN, sp. act. 2.5 Ci mmol⁻¹) and 1 or 10 μM of test ligands. Incubations were stopped by dilution in ice-cold buffer, filtered and rinsed on a Brandell cell harvester, dried and counted with a Packard scintillation counter. Specific binding was defined as the binding difference in the presence and absence of unlabeled paroxetine. Non-specific binding was defined by adding 1 μM paroxetine. Assay data were run in triplicate and repeated three times.
2.6 Data Analysis

All statistics (means, standard errors of the mean (SEM), t tests and ANOVA, Pearson correlation coefficients(r), and graphical procedures were conducted with PSI-Plot (Version 8) software (Poly Software International), Prism (version 4.0c), or using a H-P Graphing Calculator, HP48. Experiments were with a minimum of n = 3, in triplicate. Most experiments were n = 3-5.

3. RESULTS AND DISCUSSION

The compounds examined in this study (Tables 1 and 2) were designed to maximize high affinity binding at H5HT1aR and to achieve maximal inhibition at SERT. IC 50's were determined at H5HT1aR in a cell culture system as outlined in Methods; these values were then converted to Ki's (Table 1 and Table 2) as determined by the Cheng-Prusoff relationship [60]. Regarding H5HT1aR, binding values ranged in activity from nearly inactive to sub-nanomolar affinities.

Those compounds giving at least low micromolar affinity generated full, hyperbolic concentration-dependent displacement relationships to the agonist, [3H] 8-OH-DPAT. An example from compound 18 is given in graphical format in (Fig. 1). This substance has the seventh rated Ki at 16 nM and the highest SERT binding (98% inhibition at 10 μM).

An interesting comparison comes from the relative affinities of these compounds for displacement at H5HT1aR versus H5HT7R; these ratios are shown in (Fig. 2). Note that Ki values for H5HT7R are from Berrade et al. [43].

Binding at SERT was determined in an in vitro setting as described in Methods. These SERT results are presented in (Tables 1) and (Table 2). Activity at the serotonin transporter (SERT), assayed at 1 and 10 μM test compound, also ranged from inactive to substantial inhibition.

There are some potentially useful analyses that can be made by bringing all of these parameters together: Ki’s at H5HT1aR; activities at SERT; and the ratio of affinities between H5HT1aR and H5HT7R. In looking at the top five compounds in each of these categories, compound 48 tops the list of Ki’s (H5HT1aR) at 0.64 nM, followed in order by #33 (1.6 nM); #32 (2 nM); #16 (7 nM); and #17 (7.8 nM). For SERT inhibition at 10 μM, the top compound is #18 (see Fig. 1 and Table 1) followed by compounds 40, 41, 23 and 33. In the H5HT1aR vs. H5HT7R comparison (Fig. 2), the top five are #33, 48, 32, 18, and 42 (in this figure a high value indicates that affinity is greater at H5HT1aR than at H5HT7R). Of particular note is the observation that three of these compounds: #3, 33, 48 and 42 make two of these three lists, while compound 33 can be found on all three.

![Fig. 1. Concentration-Dependency of a Prototypical Compound (18). Procedures for the binding assays are described in Materials and Methods](image-url)

Briefly, membranes expressing H5HT1aR were exposed to 0.5 nM [3H] 8-OH-DPAT for 30 min. at 4°C in the presence of varying concentrations of compound 18. Reactions were stopped in cold binding buffer, and bound receptor was isolated by filtration, and quantified by liquid scintillation.
Fig. 2. Graphical Comparison of H5HT1aR vs. H5HT7R Binding Activities. Ratios were derived from H5HT1aR affinities presented in this communication and H5HT7R affinities previously published by Berrade et al. [43]

Binding affinities for H5HT1aR under investigation in this communication were determined as detailed in Materials and Methods. Briefly, membranes expressing H5HT1aR were exposed to 0.5 nM [3H] 8-OH-DPAT for 30 min. at 4°C in the presence of varying concentrations of the compounds under investigation. Reactions were stopped in cold binding buffer, and bound receptor was isolated by filtration, and quantified by liquid scintillation.

The larger a value in this calculation, the greater the affinity at H5HT1aR compared to H5HT7R.

Top rated compounds are found in both series (Table 1 [ketones] and Table 2 [hydroxyls]) in all categories. While the very best compounds for H5HT1aR affinity and ratio of H5HT1aR vs. H5HT7R affinities are found in (Table 2), the top-rated SERT inhibitor is in (Table 1). Of the compounds that are in the top five for two or more of the parameters, one is from (Table 1) with three from (Table 2).

The ketone versus hydroxyl designation does not seem to be discriminatory for SERT inhibitory activity. On the other hand, 6 of the top 10 ligands differentiating between H5HT1aR and H5HT7R binding are ketones (Fig. 2). Four of the top five (32, 33, 48, 42) however, including the top three (33, 48, 32) are alcohols. Compound 33, in the top five for all three parameters, is an alcohol.

Compound 48 which has the highest affinity for H5HT1aR equals or betters the ability of 8-OH-DPAT for binding to H5HT1aR (about 1 nM) (Table 2). Since there are many ligands that have high affinity for the H5HT1aR, this characteristic of compound 48 may not be especially noteworthy. However, 8-OH-DPAT does not readily discriminate in binding to H5HT1aR versus H5HT7R whereas compound 48 does. This property of a number of new ligands studied here will be discussed later in this section. Compound 48 also nearly reduces SERT binding to less than half at 10 μM. Further, compound 18 (which is number four in the receptor discrimination category) reduces SERT binding to near zero at 10 μM, making it an attractive pharmacological and therapeutic candidate. There are two additional compounds (33 and 32) with Ki’s for H5HT1aR at or below 2 nM, putting them in the range of 8-OH-DPAT.

Compound 18, (Table 1) and (Fig. 1), deserves special attention due to its leading SERT inhibitory activity in combination with solid affinity for H5HT1aR. At 10 μM this compound produces near complete inhibition of SERT. With a Ki of 16 nM at H5HT1aR compound 18 has 25 times lower affinity for the receptor than does compound 48; nevertheless, 16 nM is a very respectable affinity. Since the primary goal of this research was to produce drugs with dual SERT/H5HT1aR activity, compound 18 may be one of the best products depending on how the two activities are prioritized in ranking the candidates. These two characteristics are vital to the thesis that these compounds bring important properties to bear as potential anti-depressant therapeutic agents.
4. CONCLUSION

BTPN (compound 15) to H5HT1aR seems to be based on the thermodynamic data, binding of ketones. (48,33,32) while the n H5HT1aR agents are from the hydroxyl subset alcohol, three of the top five high affinity the two main groups, and the other with an subgroup, one with a ketone moiety conjugating benzothiophene group. In the present study, two activity is related to the presence of arylpiperazine function while SERT inhibitory affinity for H5HT1aR is conferred by the postulated by Berrade et al. [43] are upheld: compounds, the structure 33 may be the lead candidate for a substantial experimental and therapeutic tool. Compound 18 may not be far behind as a lead candidate.

To begin the process of better understanding the receptor binding properties of these compounds, we measured the thermodynamics [61,62] for one of the compounds, compound 15. This compound has a moderately high affinity for H5HT1aR of 10 nM, and a standard free energy for binding of negative 50 kJoules per mole. The standard enthalpy is 28 kJoules per mole, while the standard entropy is 261 Joules per mole. These values compare to negative 52 kJoules per mole, 13 kJoules per mole, and 220 Joules per mole, respectively, for the agonist [3H] 8-OH-DPAT [51].

**CONSENT**

It is not applicable.

**ETHICAL APPROVAL**

It is not applicable.

**ACKNOWLEDGEMENTS**

The authors would like to express deepest appreciation to the Department of Biomedical and Pharmaceutical Sciences, the Skaggs School of Pharmacy, the College of Health Professions and Biomedical Sciences, all of The University of Montana (UM), Missoula. Without the resources and human support of these units and The University, the project could not have occurred. Special thanks to Dr. Jerry R. Smith and Kevin Trout for their editorial assistance; Lynn Parker and Emily Lund for their technical expertise. Research was conducted under the generous and essential sponsorship of the following NIH grants: UM-CHPBS Endowment Fund Program NIH S21-MD000236, RR10169 and GM/OD 54302-01/02, and P20 RR 15583 to the UM COBRE Center for Structural and Functional Neurosciences from NCRR.Prof. Salvatore Guccione would like to express deepest appreciation to Prof. Filippo Caraci for the helpful discussion and suggestions.
COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55-68.
2. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Duldava S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634):805-809.
3. Joels M, Baram TZ. The neuro-symphony of stress. Nat Rev Neurosci. 2009; 10(6):459-466.
4. Krishnan V, Nestler EJ. Linking molecules of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011; 13(1):22-37.
5. Mao P. Potential antidepressant role of neurotransmitter CART: Implications for Mental Disorders. Depress Res Treat. 2011;2011(2090):6303-6314.
6. Borroto-Escuela DO, Romero-Fernandez W, Perez-Alea M, Narvaez M, Tarakanov AO, Mudó G, et al. The existence of FGFR1-5-HT1A receptor heterocomplexes in midbrain 5-HT neurons of the rat: relevance for neuroplasticity. J Neurosci. 2012;32(18):6295-6303.
7. Burke TF, Advani T, Adachi M, Monteggia LM, Hensler JG. Sensitivity of hippocampal 5-HT1A receptors to mild stress in BDNF-deficient mice. Int J Neuropsychopharmacol. 2013;16 (3):631-645.
8. Barnes NM, Sharp T. A review of central 5-HT receptors and their functions. Neuropharm. 1999;38(8):1083-1152.
9. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108(5):1614-1641.
10. Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta. 2007;1768(4):976-993.
11. Jans LA, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: Assumptions, experimental evidence and implications. Mol Psychiatry. 2007;12(6):522-543.
12. Le Francois B, Czesak M, Steubl D, Albert PR. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology. 2008; 55(6):977-985.
13. Franklin TB, Linder N, Russig H, Thony B, Mansuy IM. Influence of early stress on social abilities and serotonergic functions across generations in mice. Plos One. 2011;6(7):e21842.
14. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71(7):839-854.
15. Longone P, DI Michele F, D’Agati E, Romeo E, Pasini A, Rupprecht R. Neurosteroids as neuromodulators in the treatment of anxiety disorders. Front Endocrinol (Lausanne). 2011;2(55):1-9.
16. Popoli M, Yan Z, Mc Ewen BS, Sanacora G. The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011; 13(1):22-37.
17. Albert PL, Vahid-Ansari F, Luckhart C. Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: Pivotal role of pre- and post-synaptic 5HT1a receptor expression. Front Behav Neurosci. 2014;8(199):1-13.
18. Rachalski A, Alexandre C, Bernard JF, Saurini F, Lesch KP, Hamon M, et al. Altered sleep homeostasis after restraint stress in 5-HTT knock-out male mice: A role for hypocretins. J Neurosci. 2009; 29(49):15575-15585.
19. Adams JD, Parker KK. Extracellular and Intracellular Signaling. 1th ed. Cambridge: Royal Society of Chemistry; 2011.
20. Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology (Berl). 2011;213 (2-3):265-287.
21. Filip M, Bader M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep. 2009;61(5):761-777.
22. Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB. Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther. 2011;129(2):120-148.
23. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009; 459(7245):356-363.
features for functional selectivity at Serotonin Receptors. Science. 2013; 340(6132):615-619.

25. Martel JC, Ormire AM, Leduc N, Assie MB, Cussac D, Newman-Tancred A. Native rat hippocampal 5-HT1A receptors show constitutive activity. Mol Pharmacol. 2007;71(3):638-643.

26. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry. 2009; 66(7):627-635.

27. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009;88(1):17-31.

28. Kishi T, Tsunoka T, Ikeda M, Kawashima K, Okochi T, Kitajima T, et al. Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. J Hum Genet. 2009;54(11):629-633.

29. Czesak M, Le François B, Millar AM, Deria M, Daigle M, Visvader JE, et al. Increased serotonin-1A (5-HT1A) autoreceptor expression and reduced raphe serotonin levels in deformed epidermal autoregulatory factor-1 (Deaf-1) gene knock-out mice. J Biol Chem. 2012; 287(9):6615-6627.

30. Beyer CE, Lin Q, Platt B, Malberg J, Hornby G, Sullivan KM, et al. Preclinical characterization of WAY-211612: A dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant. Br J Pharmacol. 2009; 157(2):307-319.

31. Claes S. Glucocorticoid receptor polymorphisms in major depression. Ann NY Acad Sci. 2009;1179:216-228.

32. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis. 2013;52:49-65.

33. Resslief LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimarães FS. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009; 156(1):181-188.

34. Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol. 2007;555(2-3):156-163.

35. Soares Vde P, Campos AC, Bortoli VC, ZangrossiH, Jr, Guimarães FS, Zuardi AW. Intra-dorsal peri-aqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res. 2010;213(2):225-229.

36. Martínez J, Pérez S, Oficialdeguí AM, Heras B, Órús L, Villanueva H, et al. New 3-[4-(aryl) piperazin-1-yl]-1 (benzo [b] thiophen-3-yl) propane derivatives with dual action at 5-HT1A serotonin receptors and serotonin transporter as a new class of antidepressants. Eur J Med Chem. 2001; 36(1):55-61.

37. Martínez-Esparza J, Oficialdeguí AM, Pérez-Silanes S, Heras B, Órús L, Palop JA, et al. New 1-aryl-3-[4-arylpiperazin-1-yl) propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants. J Med Chem. 2001; 44(3):418-428.

38. Órús L, Pérez-Silanes S, Oficialdeguí AM, Martínez-Esparza J, Del Castillo JC, Mourelle M, et al. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors. J Med Chem. 2002; 45(19):4128-4139.

39. Pérez-Silanes S, Berrade L, García-Sánchez RN, Mendoza A, Galiano S, Martín B, et al. New 1-aryl-3-substituted propanol derivatives as antimalarial agents. Molecules. 2009;14(10):4120-4135.

40. Butler SG, Meegan MJ. Recent developments in the design of antidepressive therapies: Targeting the serotonin transporter. Curr Med Chem. 2008;15(17):1737-1761.

41. Sghendo L, Mifsud J. Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. J Pharm Pharmacol. 2012; 64(3):317-325.

42. Stahl SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry. 2010;71(11):1414-1415.

43. Berrade L, Aisa B, Ramírez MJ, Galiano S, Guccione S, Molzau LR, et al. Novel benzo [b] thiophene derivatives as new potential antidepressants with rapid onset of action. J Med Chem. 2011;54(8):3086-3090.

44. Ciranna L, Catania MV. 5HT7 Receptors as modulators of neuronal excitability,
synaptic transmission and plasticity: Physiological role and possible implications in autism spectrum disorders. Front Cell Neurosci. 2014;8(250):1-17.

45. Volk B, Gacsályi I, Pallagi K, Poszávácz L, Gyönös I, Szabó E, et al. Optimization of (aryl)piperazinebutyloxindoles exhibiting selective 5-HT1A receptor antagonist activity. J Med Chem. 2011;54(19):6657-6669.

46. Renner U, Zeug A, Woehler A, Niebert M, Dityatev A, Dityateva G, et al. Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J Cell Sci. 2012;125(10):2486-2499.

47. Guccione S, Doweyko AM, Chen H, Barretta GU, Balzano F. 3D-QSAR using 'multiconformer' alignment: The use of HASL in the analysis of 5-HT1A thienopyrimidine ligands. J Comput Aided Mol Des. 2000;14(7):647-657.

48. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037-1043.

49. Thiagajar HV, Russo EB, Burnett A, Goldstein E, Thompson CM, Parker KK. Binding properties of dipropyltryptamine at the human 5-HT1a receptor. Pharmacology. 2005;74(4):193-199.

50. Thiagajar HV, Ortiz TC, Devereaux MC Jr, Seaver B, Hall B, Parker KK. Regulation of G proteins by human 5-HT1a receptor TM3/i2 and TM5/i3 loop peptides. Neurochem Int. 2007;50(1):109-118.

51. Hall B, Burnett A, Christians A, Halley C, Goldstein E, Thiagajar HV, et al. Thermodynamics of Peptide and Non-Peptide Interactions with the Human 5HT1a Receptor. Pharmacology. 2010;86(1):6-14.

52. Burnett A, Goldstein E, Christians A, Hall B, Parker KK. Thermodynamic Properties of the Human 5HT1a Receptor. Soc Neurosci Abstr. 2003;29:362.

53. Hall B, Squires C, Parker KK. Energetics at the Human 5HT1a Receptor Loop 2-Gi Interface. Soc Neurosci Abstr. 2007;33:465-468.

54. Dalpiaz A, Borea PA, Gessi S, and Gilli G. Binding Thermodynamics of 5-HT1a Receptor Ligands. Eur J Pharmacol. 1996;19(1):107-114.

55. Fargin A, Raymond JR, Lohse MJ, Koblika BK, Caron MG, Lefkowitz RJ. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1a receptor. Nature. 1988;335(6188):358-360.

56. Koblika BK, Frielle T, Collins S, Yang-Feng T, Koblika TS, Francke U, et al. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature. 1987;329(6134):75-79.

57. Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN. The recombinant 5-HT1a receptor: G protein coupling and signaling pathways. Br J Pharmacol. 1999;127(8):1751-1764.

58. Bradford MM. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248-254.

59. Gerdes JM, De Fina SC, Wilson PA, Taylor SE. Serotonin transporter inhibitors: Synthesis and binding potency of 2'-methyl- and 3'-methyl-6-nitroquipazine. Bioorg Med Chem Lett. 2000;10(23):2643-2646.

60. Cheng YC, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of the inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099-3108.

61. Zahniser NR, and Molinoff PB. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]Spiropiperidin rat striatum. Mol Pharmacol. 1983;23(2):303-309.

62. Hitzemann, R. Thermodynamic aspects of drug-receptor interactions. Trends Pharmacol Sci. 1988;9(11):408-411.

63. Kozaric-Kovacic D. Psychopharmacotherapy of posttraumatic stress disorder. Croat Med J. 2008;49(4):459-475.

64. Vermetten E, Lanius RA. Biological and clinical framework for posttraumatic stress disorder. Handb Clin Neurol. 2012;106:291-342.
65. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP, et al. The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology. 2011;36(3):638-651.

© 2015 Alfonsino et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://sciencedomain.org/review-history/10238